Hemoglobin levels above 11 g/dL in patients with chronic kidney disease and dialysis patients have been associated with death, cardiovascular risk, and stroke.
The US FDA recommends that patients with chronic kidney diseae receive Erythropoietin-stimulating agent therapy only when Hb is below 10 g/dL and patients on dialysis should maintain their hemoglobin in the 10-11 g/dL range.
No comments:
Post a Comment